Physician profile
Manohar Shetty
NPI 1750350435
$1,917.36
in general payments reported to CMS, 2019-2025
15 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $334 · 2021: $344 · 2022: $234 · 2023: $175 · 2024: $286 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.63 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $324.15 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $321.03 | 2019-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $117.00 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.78 | 2020-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2020 | |
| Neurocrine Biosciences, INC. | $86.56 | 2019-2021 | |
| Alkermes, INC. | $78.22 | 2021-2023 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $55.86 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $44.40 | 2019-2020 | |
| Allergan, INC. | $41.92 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.54 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $19.75 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.43 | 2024 | Abilify Maintena |
| Indivior INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manohar Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.